- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01867606
Serum Bovine Immunoglobulin Protein Isolate in Improving Quality of Life and Post-Operative Recovery in Patients With Gynecological Cancer After Undergoing Surgery
MC1267, A Randomized, Blinded Pilot Placebo-Controlled Trial With Oral Serum Bovine Immunoglobulin (SBI) to Assess Quality of Life and the Faster Post-Operative Recovery of Gynecological Cancer Patients
Study Overview
Status
Conditions
Detailed Description
PRIMARY OBJECTIVES:
I. To compare the time-to-quality of life (QOL) improvement from baseline in postoperative gynecological cancer patients who are receiving oral serum bovine immunoglobulin (SBI) vs. placebo.
SECONDARY OBJECTIVES:
I. To compare the surgical complication rates between oral SBI vs. placebo up to 1 month post-surgery (safety endpoint).
II. To compare the QOL, as derived from the previously-validated Symptom Distress Scale, the Postoperative Quality of Life questionnaire (PQL), and the uniscale (overall QOL item) between patients receiving oral SBI vs. placebo.
III. To compare the grade 2 or worse adverse event rates for patients receiving oral SBI vs. placebo.
IV. To characterize the adverse event profile of oral SBI in postoperative gynecological cancer patients (safety endpoint).
V. To compare supplement adherence between patients receiving oral SBI vs. placebo.
TERTIARY OBJECTIVES:
I. To explore whether candidate biomarkers are modified with SBI versus placebo.
II. As part of ongoing research, to bank leftover blood samples for future studies.
III. To explore quality of life during postoperative recovery after gynecologic surgery, regardless of whether or not patients take the study intervention/placebo or discontinue intervention/placebo early.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive SBI orally (PO) twice daily (BID) on days 1-28.
ARM II: Patients receive placebo PO BID on days 1-28.
In both arms, treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 4 weeks.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of gynecological cancer of any type or strong suspicion for cancer
- Patients must have begun postoperative oral intake of food prior to registration
- Open laparotomy or laparoscopic surgery undertaken with cancer therapeutic intent (not a subsequent surgery to manage a postoperative complication) that had occurred =< 7 days prior to registration and that entailed more than a simple hysterectomy
- Creatinine =< 1.5 x the upper limit of normal (ULN)
- Absolute neutrophil count >= 1500/mm^3
- Platelet count >= 100,000/mm^3
- Ability to complete questionnaire(s) by themselves or with assistance
- Provide informed written consent
- Negative (serum) pregnancy test done =< 7 days prior to randomization, for women of childbearing potential only
- Willing to provide mandatory baseline blood samples for correlative research purposes
Exclusion Criteria:
- Symptomatic and/or untreated brain metastases
- Ongoing parenteral nutrition (receiving intravenous nutrition support at the time of enrollment); note: patients may be receiving maintenance intravenous (IV) fluids
- Current enrollment in any other trial that entails the concurrent administration of any other agent designed to enhance postoperative recovery
- Allergy to beef
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm I (serum-derived bovine immunoglobulin protein isolate)
Patients receive SBI PO BID on days 1-28. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. |
Correlative studies
Ancillary studies
Ancillary studies
Other Names:
Given PO
Other Names:
|
Placebo Comparator: Arm II (placebo)
Patients receive placebo PO BID on days 1-28. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. |
Correlative studies
Ancillary studies
Ancillary studies
Other Names:
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time-to-QOL Improvement Defined as Any Increase in the QOL Score Measured Using the Total Score of the 14-item Postoperative Quality of Life (PQL) Tool
Time Frame: up to 25 months
|
For this endpoint, the total QOL score could range from 1 to 140 (0 being the worst and 140 being the best).
The primary analysis will be a comparison of oral SBI vs. placebo using a two-sided log-rank test between the 2 Kaplan-Meier curves.the
total score of the 14-item Postoperative Quality of Life (PQL) tool [15] will be used, where the total score could range from 0 to 140 (0 being the worst and 140 being the best).
These scores will be converted to the percentage scale, where a score of 140 will be converted to 100 and a score of 0 will remain as 0. This QOL will be measured weekly for the entire 12 week length of the study and at the end of the intervention.
QOL improvement will be defined as at least a 10 point increase in the QOL score from baseline, on the percentage scale.
|
up to 25 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Adverse Event Rates for Grade 2 or Higher Adverse Events, Graded According to the Common Terminology Criteria for Adverse Events Version 4.0
Time Frame: up to 25 months
|
Frequency tables will be reviewed to determine adverse event patterns, this data is reported in the adverse events section of this report.
Below is the number of patients that experienced an adverse event greater than or equal to 2.
|
up to 25 months
|
Surgical Complication Rates
Time Frame: Up to 1 month post-surgery
|
Compared between the 2 arms using Chi-Square or Fisher's Exact tests.
|
Up to 1 month post-surgery
|
Intervention Compliance Assessed Using the Compliance Questionnaire
Time Frame: up to 25 months
|
The frequency and percentage for each Compliance Questionnaire category will be summarized descriptively by cycle and by intervention arm.
In addition, cycle by cycle compliance data will be compared between the 2 arms using a Chi-square test.
|
up to 25 months
|
Change in QOL Measured Using the 14-item PQL Tool, Uniscale, and the Previously-validated Symptom Distress Scale
Time Frame: up to 25 months
|
All 14 of the individual items from the PQL tool, along with the 4 additional items after the PQL questions will be analyzed and compared between the 2 intervention arms.
Differences between post-randomization and baseline QOL scores will be analyzed and compared between the 2 arms using a Wilcoxon Rank-sum test.
Also, other graphical and statistical methods will be used to compare the QOL between the 2 arms over time.
For this endpoint, the total QOL score could range from 1 to 140 (0 being the worst and 140 being the best).
These scores will be converted to the percentage scale, where a score of 140 will be converted to 100 and a score of 0 will remain as 0. This QOL will be measured weekly for the entire 12 week length of the study and at the end of the intervention.
QOL improvement will be defined as at least a 10 point increase in the QOL score from baseline, on the percentage scale.
|
up to 25 months
|
Change in QOL in Patients Who do Not Start Intervention or Discontinue Early, Measured Using the 14-item PQL Tool, Uniscale, and the Previously-validated Symptom Distress Scale
Time Frame: Baseline up to 25 months
|
Analysis will be descriptive in nature to see if these patients have a poorer QOL than patients who stay on study.
|
Baseline up to 25 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Aminah Jatoi, M.D., Mayo Clinic
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MC1267 (Other Identifier: Mayo Clinic)
- NCI-2013-00866 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Female Reproductive Cancer
-
European Institute of OncologyUnknownFemale Reproductive CancerItaly
-
Pennington Biomedical Research CenterCompletedFemale Reproductive Problem | Male Reproductive ProblemUnited States
-
University Hospital, ToulouseTerminatedFemale Reproductive Problem | Male Reproductive ProblemsFrance
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMalignant Female Reproductive System Neoplasm | Recurrent Malignant Female Reproductive System Neoplasm | Metastatic Cervical CancerUnited States
-
Queensland Centre for Gynaecological CancerCompletedFemale Reproductive ProblemAustralia
-
Jonsson Comprehensive Cancer CenterAstraZenecaActive, not recruitingMetastatic Malignant Female Reproductive System Neoplasm | Platinum-Resistant Malignant Female Reproductive System Neoplasm | Recurrent Malignant Female Reproductive System Neoplasm | Refractory Malignant Female Reproductive System NeoplasmUnited States
-
University of SaskatchewanCanadian Institutes of Health Research (CIHR)Completed
-
Tata Memorial CentreTerminatedGastrointestinal Cancer | Malignant Female Reproductive System Neoplasm | Urological CancerIndia
-
Advocate Health CareTerminatedBenign Female Reproductive System NeoplasmUnited States
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedFemale Reproductive CancerUnited States
Clinical Trials on laboratory biomarker analysis
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Myeloblastic Leukemia Without Maturation (M1) | Childhood Acute Myelomonocytic Leukemia (M4) | Childhood Acute Myeloid Leukemia/Other Myeloid MalignanciesUnited States